Clinton Foundation Appeals To Generic Industry To Expand Into Poor Countries
Executive Summary
MIAMI BEACH, Fla. - Ira Magaziner, the chairman of the Clinton Foundation HIV/AIDS Initiative, used a speaking engagement to deliver a pitch to the generics industry: come to developing countries to make a lot of money and help people gain access to low-cost drugs
You may also be interested in...
Triple HIV combo for children approved under PEPFAR
The first triple-combination drug for treating HIV-infected children under the age of 12 years receives tentative approval from FDA Aug. 13 as part of the President's Emergency Plan for AIDS Relief. Approved as a 505 (b)(2) NDA, the twice-daily dissolvable tablet from Cipla combines lamivudine (GlaxoSmithKline's Epivir), stavudine (Bristol-Myers Squibb's Zerit) and nevirapine (Boehringer Ingelheim's Viramune). The tablet formulation makes the drug suitable for use in regions with high temperatures and high humidity and enables treatment of children weighing as little as 5 kg, Division of Antiviral Products Director Debra Birnkrant notes. FDA also gives tentative approval under PEPFAR for nevirapine tablets to be used with antiretrovirals for treating HIV-1...
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.